Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions
The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396426/ |
| id |
pubmed-4396426 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-43964262015-04-20 Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions Kaja, Simon Shah, Anna A Haji, Shamim A Patel, Krishna B Naumchuk, Yuliya Zabaneh, Alexander Gerdes, Bryan C Kunjukunju, Nancy Sabates, Nelson R Cassell, Michael A Lord, Ron K Pikey, Kevin P Poulose, Abraham Koulen, Peter Original Research The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy deficits. A case–control study of 18 subjects with a history of RVO as well as six healthy volunteers is presented. Serum Nampt levels were quantified using a commercially available enzyme-linked immunosorbent assay kit. Serum Nampt levels were 79% lower in patients with a history of RVO compared with that in healthy volunteers (P<0.05). There was no statistically significant difference among the types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemiretinal vein occlusions (n=3), and central retinal artery occlusions (n=3; P=0.69). Further studies are needed to establish the temporal kinetics of Nampt expression and to determine whether Nampt may represent a novel biomarker to identify at-risk populations, or whether it is a druggable target with the potential to ameliorate the long-term complications associated with the condition, ie, macular edema, macular ischemia, neovascularization, and permanent loss of vision. Dove Medical Press 2015-04-07 /pmc/articles/PMC4396426/ /pubmed/25897200 http://dx.doi.org/10.2147/OPTH.S80784 Text en © 2015 Kaja et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Kaja, Simon Shah, Anna A Haji, Shamim A Patel, Krishna B Naumchuk, Yuliya Zabaneh, Alexander Gerdes, Bryan C Kunjukunju, Nancy Sabates, Nelson R Cassell, Michael A Lord, Ron K Pikey, Kevin P Poulose, Abraham Koulen, Peter |
| spellingShingle |
Kaja, Simon Shah, Anna A Haji, Shamim A Patel, Krishna B Naumchuk, Yuliya Zabaneh, Alexander Gerdes, Bryan C Kunjukunju, Nancy Sabates, Nelson R Cassell, Michael A Lord, Ron K Pikey, Kevin P Poulose, Abraham Koulen, Peter Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| author_facet |
Kaja, Simon Shah, Anna A Haji, Shamim A Patel, Krishna B Naumchuk, Yuliya Zabaneh, Alexander Gerdes, Bryan C Kunjukunju, Nancy Sabates, Nelson R Cassell, Michael A Lord, Ron K Pikey, Kevin P Poulose, Abraham Koulen, Peter |
| author_sort |
Kaja, Simon |
| title |
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| title_short |
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| title_full |
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| title_fullStr |
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| title_full_unstemmed |
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| title_sort |
nampt/pbef/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
| description |
The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy deficits. A case–control study of 18 subjects with a history of RVO as well as six healthy volunteers is presented. Serum Nampt levels were quantified using a commercially available enzyme-linked immunosorbent assay kit. Serum Nampt levels were 79% lower in patients with a history of RVO compared with that in healthy volunteers (P<0.05). There was no statistically significant difference among the types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemiretinal vein occlusions (n=3), and central retinal artery occlusions (n=3; P=0.69). Further studies are needed to establish the temporal kinetics of Nampt expression and to determine whether Nampt may represent a novel biomarker to identify at-risk populations, or whether it is a druggable target with the potential to ameliorate the long-term complications associated with the condition, ie, macular edema, macular ischemia, neovascularization, and permanent loss of vision. |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396426/ |
| _version_ |
1613211515952824320 |